Otsuka Pharmaceutical is a large pharma headquartered in Japan. Over the past three years, Otsuka Pharmaceutical has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (1 deal).
Deals (12mo)
1
Active Trials
20
Top Modality
Small Molecules
Focus Area
Rare Disease
Therapeutic areas and modalities where Otsuka Pharmaceutical is most active based on deal history and clinical trial data.
Key indicators of Otsuka Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Otsuka Pharmaceutical is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Otsuka Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Otsuka Pharmaceutical include Rare Disease (1 deal and trial). In terms of modality, Otsuka Pharmaceutical has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Otsuka Pharmaceutical and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Otsuka Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,600+ real biopharma licensing deals